OTCMKTS:VODG Vitro Diagnostics (VODG) Stock Price, News & Analysis $0.40 0.00 (0.00%) As of 10/15/2020 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Vitro Diagnostics Stock (OTCMKTS:VODG) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vitro Diagnostics alerts:Sign Up Key Stats Today's Range$0.40▼$0.4050-Day Range$0.40▼$0.4052-Week Range$0.13▼$1.04VolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewVitro Diagnostics, Inc., doing business as Vitro Biopharma, focuses on the development, manufacture, and distribution of stem cell products and related tools for use in research, drug discovery, and clinical trials in the United States. Its stem cell technology includes cell lines, supporting products, and methods for generation and differentiation of stem cells into products for the treatment of diseases, such as heart disease, arthritis, multiple sclerosis, brain injury, autism, stroke, Parkinson's, and Alzheimer's diseases. The company also offers Tools for Stem Cell and Drug Discovery that provide researchers basic tools needed to advance stem cell technology, including stem cells and their derivatives; media for growth and differentiation of stem cells; and tools for measurement of stem cell quality, potency, and response to toxic agents. In addition, it offers MSC-Gro, a cell culture media product; MSC cell line for the treatment of skeletal muscular conditions, such as tendonitis, ligament injury, osteoarthritis and accelerated bone fracture healing, etc.; and testing and therapies related to endogenous stem cell activation. Further, the company provides diagnostic testing of stem cell activation and determination of stem cell functional status; and cell-based assays for discovery of novel stem cell activation agents and drugs for the treatment of osteoporosis. Vitro Diagnostics, Inc. was founded in 1986 and is based in Golden, Colorado.Read More… Remove Ads Receive VODG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vitro Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address VODG Stock News HeadlinesThermo Fisher’s Oncomine gains FDA approval as brain tumor diagnosticOctober 22, 2024 | msn.comWHO lists first mpox in vitro diagnostic test under Emergency Use ListingOctober 6, 2024 | msn.comClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code... And since then, "in the know" patriots have quietly used this same "Trump loophole" to shield their life savings from the economic chaos. But with Trump now forcefully bringing back millions of manufacturing jobs from Mexico, China, and the entire BRICS anti-dollar coalition...April 14, 2025 | American Alternative (Ad)St. Louis-based biotech firm Leinco Technologies makes acquisitionSeptember 5, 2024 | bizjournals.comGlobal in-vitro diagnostics market to grow at CAGR 4.21% by 2028May 24, 2024 | msn.comQuidelOrtho Appoints Abbott Laboratories Executive as Next CEOMay 2, 2024 | marketwatch.comAgilent’s GenetiSure Dx diagnostic test secures IVDR certificationApril 18, 2024 | msn.comFertility clinic blames return of IVF tourism for revenue slump to €8mApril 10, 2024 | msn.comSee More Headlines VODG Stock Analysis - Frequently Asked Questions How have VODG shares performed this year? Vitro Diagnostics' stock was trading at $0.40 at the start of the year. Since then, VODG shares have increased by 0.0% and is now trading at $0.40. View the best growth stocks for 2025 here. How do I buy shares of Vitro Diagnostics? Shares of VODG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vitro Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vitro Diagnostics investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), American Battery Technology (ABML), Biogen (BIIB), Devon Energy (DVN), Processa Pharmaceuticals (PCSA) and Akero Therapeutics (AKRO). Company Calendar Today4/14/2025Fiscal Year End10/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:VODG CIK793171 Webwww.vitrobiopharma.com Phone303-999-2130Fax469-633-0088Employees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,870,000.00 Net Margins-531.95% Pretax Margin-532.00% Return on EquityN/A Return on Assets-149.85% Debt Debt-to-Equity RatioN/A Current Ratio0.10 Quick Ratio0.09 Sales & Book Value Annual Sales$1.86 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (OTCMKTS:VODG) was last updated on 4/14/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredTrump’s betrayal exposed Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vitro Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vitro Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.